The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo

Idelalisib is a highly selective oral inhibitor of PI3Kδ indicated for the treatment of patients with relapsed chronic lymphocytic leukemia in combination with rituximab. Despite additive clinical effects, previous studies have paradoxically demonstrated that targeted therapies potentially negativel...

Descripción completa

Detalles Bibliográficos
Autores principales: Palazzo, Adam, Herter, Sylvia, Grosmaire, Laura, Jones, Randy, Frey, Christian R., Limani, Florian, Bacac, Marina, Umana, Pablo, Oldham, Robert J., Marshall, Michael J. E., Cox, Kerry L., Turaj, Anna H., Cragg, Mark S., Klein, Christian, Carter, Matthew J., Tannheimer, Stacey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AAI 2018
Materias:
Clinical and Human Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857647/
https://www.ncbi.nlm.nih.gov/pubmed/29453281
http://dx.doi.org/10.4049/jimmunol.1700323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857647/
https://www.ncbi.nlm.nih.gov/pubmed/29453281
http://dx.doi.org/10.4049/jimmunol.1700323

Ejemplares similares